Quick Answer
Aldeyra Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
Aldeyra Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $15.00M | — |
| 2023 | $0.00 | -100.0% |
| 2022 | $14.92M | -3.7% |
| 2021 | $15.50M | +35.6% |
| 2020 | $11.43M | -21.3% |
| 2019 | $14.53M | +1090.6% |
| 2017 | $1.22M | -1.5% |
| 2016 | $1.24M | +2.3% |
| 2015 | $1.21M | +3.0% |
| 2014 | $1.18M | +4.1% |
| 2013 | $1.13M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | — |
| June 30, 2025 | $0.00 | — | -100.0% |
| March 31, 2025 | $15.10M | — | +0.7% |
| December 31, 2024 | $15.00M | — | +0.0% |
| September 30, 2024 | $15.00M | +464.5% | — |
| March 31, 2024 | $0.00 | -100.0% | — |
| December 31, 2023 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $2.66M | -19.6% | -73.8% |
- Aldeyra Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2013–2025 period, Aldeyra Therapeutics, Inc.’s long-term debt has declined by 100.0% (from $1.13 million to $0.00).
- The most recent figure is from Aldeyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: